NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's President & CEO, Mike Kelly, will engage in a fireside chat on February 11, 2025, at 8:40 a.m. EST.
The conference, scheduled for February 11-12, 2025, will be held in a virtual format. NervGen's management team will be available for one-on-one virtual meetings with investors throughout the conference. A webcast of the presentation will be made available and archived for later viewing.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), un'azienda biotech in fase clinica focalizzata sulle terapie neurorestorative, ha annunciato la sua partecipazione alla prossima 35ª Conferenza Annuale sulle Scienze della Vita Oppenheimer. Il presidente e CEO dell'azienda, Mike Kelly, parteciperà a una chiacchierata informale il 11 febbraio 2025, alle 8:40 EST.
La conferenza, programmata per l'11 e il 12 febbraio 2025, si svolgerà in formato virtuale. Il team di gestione di NervGen sarà disponibile per incontri virtuali individuali con gli investitori durante tutta la conferenza. Una registrazione della presentazione sarà resa disponibile e archiviata per una visione successiva.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), una empresa biotecnológica en etapa clínica centrada en terapias neurorestauradoras, ha anunciado su participación en la próxima 35ª Conferencia Anual de Ciencias de la Salud Oppenheimer. El presidente y CEO de la compañía, Mike Kelly, participará en una charla informal el 11 de febrero de 2025, a las 8:40 a.m. EST.
La conferencia, programada para el 11 y 12 de febrero de 2025, se llevará a cabo en formato virtual. El equipo de gestión de NervGen estará disponible para reuniones virtuales individuales con inversores a lo largo de la conferencia. Se dispondrá de una grabación de la presentación, que se archivará para su visualización posterior.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF)는 신경 회복 치료에 초점을 맞춘 임상 단계의 생명공학 회사로, 다가오는 오펜하이머 제35회 연례 생명 과학 및 건강 관리 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 대통령 겸 CEO인 Mike Kelly는 2025년 2월 11일 오전 8시 40분 EST에 비공식 대화에 참여할 예정입니다.
2025년 2월 11일부터 12일까지 예정된 이 컨퍼런스는 가상 형식으로 진행됩니다. NervGen의 경영진은 컨퍼런스 기간 동안 투자자들과 1대1 가상 회의를 할 수 있습니다. 발표의 웹캐스트는 나중에 볼 수 있도록 제공되고 아카이브될 것입니다.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), une entreprise biopharmaceutique en phase clinique axée sur les thérapies neurorestauratives, a annoncé sa participation à la prochaine 35e Conférence Annuelle Oppenheimer sur les Sciences de la Santé. Le président et PDG de la société, Mike Kelly, participera à une discussion informelle le 11 février 2025 à 8h40 EST.
La conférence, prévue pour le 11 et 12 février 2025, se déroulera au format virtuel. L'équipe de direction de NervGen sera disponible pour des réunions virtuelles individuelles avec les investisseurs tout au long de la conférence. Un webinaire de la présentation sera mis à disposition et archivé pour une consultation ultérieure.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf neurorestaurative Therapien konzentriert, hat seine Teilnahme an der bevorstehenden 35. jährlichen Oppenheimer-Konferenz für Gesundheits- und Lebenswissenschaften bekannt gegeben. Der Präsident und CEO des Unternehmens, Mike Kelly, wird am 11. Februar 2025 um 8:40 Uhr EST an einem informellen Gespräch teilnehmen.
Die Konferenz, die für den 11. und 12. Februar 2025 geplant ist, findet virtuell statt. Das Management-Team von NervGen steht während der gesamten Konferenz für persönliche virtuelle Meetings mit Investoren zur Verfügung. Eine Aufzeichnung der Präsentation wird zur Verfügung gestellt und für späteres Ansehen archiviert.
- None.
- None.
Vancouver, Canada--(Newsfile Corp. - January 29, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025, at 8:40 a.m. EST. The conference is being held virtually February 11-12, 2025. Members of management will be available for virtual one-on-one investor meetings during the conference.
A webcast of the presentation will be available here and posted for replay following the event.
About NervGen
NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead molecule, NVG-291, in a Phase 1b/2a clinical trial in spinal cord injury and has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. For more information, visit www.nervgen.com and follow NervGen on X, LinkedIn, and Facebook for the latest news on the company.
About NVG-291
NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting nervous system repair. NVG-291's technology was licensed from Case Western Reserve University and is based on academic studies demonstrating the preclinical efficacy of NVG-291-R, the rodent prototype of NVG-291, in animal models of spinal cord injury. Effects of NVG-291-R reported in multiple independent academic studies include the promotion of neuroplasticity, remyelination, anti-inflammatory polarization of microglia, and functional improvement in preclinical models of spinal cord injury, stroke, and peripheral nervous system injury. NVG-291 has received Fast Track designation in spinal cord injury from the U.S. Food and Drug Administration.
Contacts
Huitt Tracey, Investor Relations
htracey@nervgen.com
604.537.2094
Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners
david.schull@russopartnersllc.com
ignacio.guerrero-ros@russopartnersllc.com
858.717.2310
646.942.5604
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation (collectively, "forward-looking statements"). Such forward-looking statements herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the subject matter to be presented at the upcoming investor conference; the objectives, planned clinical endpoints, timing, expected rate of enrollment, and timing of data readout and study design of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury; the development plans, timelines, expected benefits, and prospective target indications for NVG-300; and the creation of neurorestorative therapeutics to promote nervous system repair in settings of neurotrauma and neurologic disease.
Forward-looking statements are based on estimates and assumptions made by the company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, we have relied on various assumptions, including, but not limited to: our ability to obtain future funding on favourable terms or at all; the accuracy of our financial projections; obtaining positive results in our clinical and other trials; our ability to obtain necessary regulatory approvals; our ability to arrange for the manufacturing of our product candidates and technologies; and general business, market and economic conditions.
Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the company's most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen's profile on SEDAR+ at www.sedarplus.ca. All clinical development plans are subject to additional funding.
Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238889
FAQ
When is NervGen Pharma (NGENF) presenting at the Oppenheimer Healthcare Conference 2025?
Will the NervGen Pharma (NGENF) Oppenheimer Conference presentation be available online?
Can investors schedule one-on-one meetings with NervGen Pharma (NGENF) management at the Oppenheimer Conference?
What type of company is NervGen Pharma (NGENF)?
